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Recent studies have identified vimentin, a type III intermediate filament, among genes differentially expressed in tumours with more
invasive features, suggesting an association between vimentin and tumour progression. The aim of this study, was to investigate
whether vimentin expression in colon cancer tissue is of clinical relevance. We performed immunostaining in 142 colorectal cancer
(CRC) samples and quantified the amount of vimentin expression using computer-assisted image analysis. Vimentin expression in the
tumour stroma of CRC was associated with shorter survival. Overall survival in the high vimentin expression group was 71.2%
compared with 90.4% in the low-expression group (P¼0.002), whereas disease-free survival for the high-expression group was
62.7% compared with 86.7% for the low-expression group (P¼0.001). Furthermore, the prognostic power of vimentin for disease
recurrence was maintained in both stage II and III CRC. Multivariate analysis suggested that vimentin was a better prognostic indicator
for disease recurrence (risk ratio¼3.5) than the widely used lymph node status (risk ratio¼2.2). Vimentin expression in the tumour
stroma may reflect a higher malignant potential of the tumour and may be a useful predictive marker for disease recurrence in CRC
patients.
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Intermediate filament proteins form a dynamic cytoskeletal
network in the cell to protect them against mechanical stress and
to maintain cellular integrity (Clarke and Allan, 2002; Helfand
et al, 2004). Vimentin is a type III intermediate filament
characteristically found in cells of mesenchymal origin, that is
fibroblast, chondrocytes, macrophages, and endothelial cells
(Osborn, 1983). Vimentin was postulated to act as a scaffolding
protein to stabilise connective tissues and cells, or in signal
transduction (Herrmann et al, 2003; Eriksson et al, 2004). It was
also reported to be involved in wound healing (Eckes et al, 2000)
and lipid metabolism (Schweitzer and Evans, 1998).
Recently, an association between vimentin and tumour deve-
lopment, progression, and chemosensitivity was suggested by
various gene profiling studies (Zajchowski et al, 2001; Mellick et al,
2002; Penuelas et al, 2005). Vimentin was selectively overexpressed
in highly aggressive breast cancer cells (Zajchowski et al, 2001). It
was also included, along with eight other genes, in a test that could
sufficiently distinguish between invasive and noninvasive breast
cancer (Nagaraja et al, 2006). Expression studies also indicated
that vimentin overexpression in prostate cancer correlates with a
more malignant phenotype (Lang et al, 2002; Singh et al, 2003).
Furthermore, proteomic analysis identified the vimentin gene as
one differentially expressed in colorectal cancer compared with the
surrounding normal tissue (Alfonso et al, 2005). In regard to
chemosensitivity, vimentin expression was higher in colon
carcinoma cell clones resistant to doxorubicin, although vimentin
alone did not confer resistance (Conforti et al, 1995). Similar
findings were reported for a multidrug resistant breast cancer
subline (Bichat et al, 1997).
In this study, we evaluated the significance of vimentin
expression in colorectal cancer (CRC). Although colon cancer
cells did not express vimentin, we found that stromal vimentin
expression was quite abundant. Tumour stromal reaction is known
to be dynamic. Difficulties in quantifying changes in the tumour
stroma have limited the possibility of its utilisation in clinical
settings. Here, we attempted semiquantification using computer-
assisted imaging, and further analysed the correlation to
clinicopathological factors and patients’ survival.
MATERIALS AND METHODS
Patients
Vimentin expression was examined in a total of 142 CRC tissues of
intermediate stages, that is, stage II (n¼78) and stage III (n¼63),
based on the UICC TNM classification. The mean age of the
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spatients was 62.579.5 years, with 62 women and 80 men. The
tumours ranged in size from 0.8712.0cm (mean 5.171.8cm), and
were resected from either the colon (n¼80) or rectum (n¼62).
The mean follow-up period was 66.1729.4 months (range, 0.72–
150.0 months). The overall 5-year survival rate was 82.4% and the
5-year disease-free survival rate was 76.8%. After surgery, stage III
patients received 5-FU-based chemotherapy. Patients with stage II
CRC had no chemotherapy unless the patient requested it. The
study protocol was approved by the Human Ethics Review
Committee of the Graduate School of Medicine, Osaka University.
Histology
Tissue sections (4mm thick) were prepared from formalin-fixed
paraffin-embedded blocks. Sections were stained with hematoxylin
and eosin (H&E) solution, and reviewed by two pathologists from
the Department of Pathology, Osaka University. The histological
staging of tumours was as follows: well-differentiated adenocarci-
noma (n¼72), moderately differentiated adenocarcinoma (n¼59),
poorly differentiated adenocarcinoma (n¼5), mucinous carcinoma
(n¼5), and signet ring cell carcinoma (n¼1). The extent of stromal
reaction was evaluated as extensive, moderate, and slight according
to the criteria reported (Jass et al, 1986; Harrison et al, 1994).
Tumour budding was evaluated based on the definition reported
previously, and classified as high-grade budding and low-grade
budding accordingly (Ueno et al, 2002). Characteristics of the
tumour at the invasive margin were evaluated based on the diffuse
infiltrative features of the tumour (Jass et al,1 9 8 7 ) .
Immunohistochemistry
Expression of vimentin was studied by immunohistochemistry.
Immunostaining was performed using the Vectastain ABC
peroxidase kit (Vector Labs, Burlingame, CA, USA), as described
previously by our laboratories (Noura et al, 2002; Yamamoto et al,
2003). Tissues were sliced into 4mm sections, dewaxed in xylene,
and rehydrated in decreasing concentrations of ethanol. Sections
were subjected to endogenous peroxidase blocking in 1% H2O2
solution in methanol for 20min and then to antigen retrieval
treatment in 10mM citrate buffer, pH 6.0, for 40min in a water
bath preheated to 951C. Serum blocking was performed using 10%
normal rabbit serum for 30min at room temperature. This was
followed by incubation with primary antibodies at 41C over-
night. Both the anti-vimentin (Novocastra, Newcastle, UK) and
anti-proliferating cell nuclear antigen (PCNA) (PC10, Novocastra)
monoclonal antibodies were diluted 1:50. Anti-CD34 (Novocastra)
was used at 1:500 dilution. PCNA labelling was included as a
quality control of tissue blocks. Secondary biotinylated anti-mouse
antibody (BA2000, Vector Laboratories, Burlingame, CA, USA) was
used at a dilution of 1:100 for 30min at room temperature.
Washing was performed using phosphate-buffered saline (PBS).
Reaction product was visualised using 3,30-diaminobenzidine
(Wako Pure Chemical Industries, Osaka, Japan) as a chromogenic
substrate. Sections were counterstained with hematoxylin, dehy-
drated, and mounted. For the negative control, nonimmunised
mouse IgG (Vector Labs) was used in place of the primary
antibodies.
Computer-assisted imaging
The stained sections were viewed under a microscope equipped
with a charge-coupled device (CCD) colour camera (Olympus
Corp., Tokyo, Japan). We selected 10 fields in the ‘hot spots’ of
positivity in each specimen at high power magnification. Photos
were analysed using imaging processor Mac SCOPE software
(Mitani Corp., Fukui, Japan), where the staining area (Figure 1)
AB
CD
Figure 1 Representative sections of high vimentin expression (A) and low vimentin expression (C) in tumour stroma. Images were analysed based on the
colour selection. Image analysis figures are shown (B and D). Area labelled (in fluorescent green) was calculated accordingly. Surface area was calculated as
22.0 and 3.3%.
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swas calculated accordingly. Briefly, the investigator selected the
brown-stained areas representative of vimentin expression on the
photo. Vimentin expression in the colonic mucosal lymphocytes
was used as internal positive control. The computer would then
automatically detect the area with the same configuration on
the photo and convert the data to a percentage of the total area
in each field.
Statistical analysis
Mean values were compared using the Student’s t-test. Associa-
tions between discrete variables were assessed using the w
2 test.
The Kaplan–Meier method was used to estimate tumour
recurrence or death from CRC, and the log-rank test was used to
examine statistical significance. A Cox proportional hazards model
was used to assess the risk ratio under simultaneous contributions
from several covariates. All statistical analyses were performed
using the StatView J-5.0 programme (Abacus Concepts Inc.,
Berkeley, CA, USA). All data were expressed as the mean7s.d..
P-values of less than 0.05 were accepted as statistically significant.
RESULTS
Expression of vimentin in CRC tissue
Vimentin expression was detected in the tumour stroma region
(Figure 1). Staining was intense and homogenous. No expression
was observed in the normal colonic epithelial cells or tumour
cells. Using computer-assisted image analysis, vimentin scores
were determined (Figure 1). When 10 fields were analysed,
vimentin expression varied widely, ranging from 1.7 to 24.1%
(mean 8.874.3%). The quality of all tissue blocks was confirmed
by intense staining for PCNA in the proliferative zone of normal
colonic epithelium and germinal centres of lymphoid follicles.
Vimentin expression and clinicopathological
characteristics
Using the mean value of vimentin expression, 8.8%, as a cutoff
point, the sample population was divided into high-expression
(n¼59) and low-expression groups (n¼83). When vimentin
expression was compared with the clinicopathological parameters
listed in Table 1, an association was found between vimentin
expression and age. Other factors were not associated with
vimentin expression.
Vimentin expression and histological characteristics
at the tumour–stroma interface
Changes in the stroma may have an active role in the acquisition
of invasive phenotype of tumour cells. We tested whether vimentin
expression is associated with these histological characteristics at
the tumour–stroma interface.
Tumours displaying diffuse infiltration pattern at the invasive
front are deemed to be more aggressive. In this series, the 52.8% of
the tumours exhibited this feature whereas the remaining 47.2%
of the tumours lacked this feature. No association between this
feature and vimentin expression was found.
Tumour budding was another histological change noted at the
invasive front. This histological dedifferentiation phenomenon
was observed in immature stroma, possibly promoting tumour
progression (Ueno et al, 2004). Of the 142 CRC cases, only 27
(19.0%) showed high-grade tumour budding and the remaining
115 (81.0%) showed low-grade tumour budding. No significant
association was found between tumour budding and vimentin
expression.
We also compared vimentin expression with the extent of
stromal response. In this series of CRCs, 24 tumours (16.9%)
showed extensive stromal response, 95 (66.9%) showed moderate
response, and 23 (16.2%) showed a slight response. No association
was noted between this response and vimentin expression.
Survival analysis
For the overall and disease-free survival analysis, high vimentin
expression was significantly associated with a shorter survival.
For overall survival (Figure 2A), 5-year survival for the high-
expression group was 71.2% compared with 90.4% for the low-
expression group (P¼0.002). Similarly, as shown in Figure 2B, the
5-year disease-free survival rate was 62.7% for the high-expression
group compared with 86.7% in the low-expression group
(P¼0.001). When we further analysed the survival data for stage
II (without lymph node metastasis) and stage III (with lymph
node metastasis) CRC, we found that irrespective of the lymph
node status, vimentin expression was significantly associated with
a higher disease recurrence rate (Figure 2B). For stage II tumours,
the disease-free survival rate for the high vimentin expression
group was 71.4% compared with 92.3% in the low-expression
group (P¼0.029). Meanwhile, for stage III tumours, the disease-
free survival for the high-expression group was 45.2% compared
with 79.4% in the low-expression group (P¼0.024). However, for
overall survival (Figure 2A), an association was found only in stage
II (75.0 vs 92.2%, P¼0.031), but not in stage III (67.7 vs 87.5%,
P¼0.054). Considering that disease recurrence may provide a
Table 1 Vimentin expression and patient characteristics
Vimentin expression
Clinicopathological characteristic High Low P-value
Age 64.478.6 61.179.9 0.037
Tumour size 0.372.0 5.071.7 0.348
Gender
Male 32 48 0.670
Female 27 35
Tumour site
Colon 36 44 0.343
Rectum 23 39
Degree of differentiation
Well 27 45 0.321
Mod./poor 32 38
Depth of invasion
mp 5 8 0.812
ss 54 75
Lymph node metastasis
Absent 28 51 0.098
Present 31 32
No of lymph nodes involved
0 28 51 0.167
1–3 20 24
X41 1 8
Lymphovascular invasion
a
Absent 24 32 0.799
Present 35 51
Well¼well-differentiated adenocarcinoma, Mod.¼moderately differentiated
adenocarcinoma, Poor¼poorly differentiated carcinoma (this category included five
cases of poorly differentiated adenocarcinoma, five cases of mucinous carcinoma and
one case of signet ring cell carcinoma), mp¼muscularis propria; ss¼subserosa.
aLymphatic invasion was determined by the presence of tumour cells in lymphatic
ducts. Bold value is statistically significant (Po0.05).
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sbetter understanding of clinical prognosis, further analyses were
performed based on disease recurrence rather than overall survival
(Andre et al, 2004).
Univariate survival analyses for other clinicopathological para-
meters and a few histological characteristics at tumour–stroma
interface are summarised in Table 2. Of all parameters, lymph
node metastasis status was of prognostic value, as expected. No
other parameters showed significant prognostic value. Multivariate
analysis of vimentin expression and other histopathological factors
(Table 3) revealed that vimentin was an independent prognostic
factor for CRC disease recurrence, with the high-expression group
having a 3.5-fold greater risk of recurrence compared with the
low-expression group. The risk ratio was also higher compared
with lymph node status (relative risk of 2.2-fold). In addition,
the diffuse infiltration characteristic at the invasive front was also
shown to be an independent prognostic factor with a relative risk
of 2.3-fold.
Vimentin expression and microvascular density
Endothelial cells also display reactivity to anti-vimentin antibody.
Therefore, we also evaluated endothelial cells using antibody
against CD34. The total area stained for CD34 ranged from 0.09 to
2.42%, with a mean of 0.82%. CD34 staining accounted for less
than 10% of the area staining for vimentin. We re-examined the
prognostic value of vimentin expression after deducting the total
area staining for CD34 to test whether microvascular density
contributed to the prognostic significance of vimentin. Using the
average mean value (7.96%) of vimentin after this adjustment as a
cutoff point, a statistically significant difference (P¼0.008) was
still observed between the high-and low-expression groups.
DISCUSSION
Tissue stroma consists of a variety of matrix substances such as
interstitial collagen, fibronectin, elastin, and glycoaminoglycans
and a variety of cell types including inflammatory cells, immune
cells, fibroblasts, muscle, and vascular cells (Dvorak, 1986).
Stromal microenvironment in tumour has a crucial role in tumour
progression. It provides an interface between malignant cells and
host tissues (Bissell and Radisky, 2001). Cumulative evidence
suggests that the balance of host–tumour interdependency could
modulate the phenotype of a tumour, and thus influence the
outcome of the disease. However, appropriate markers to quantify
the stromal reaction have yet to be determined.
Stage II (n = 79) Stage III (n = 63) Entire series (n =142)
0
0.2
0.4
0.6
0.8
1
0
0.2
0.4
0.6
0.8
1
0
0.2
0.4
0.6
0.8
1
0
0.2
0.4
0.6
0.8
1
0
0.2
0.4
0.6
0.8
1
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8 10 (years)
Vim Low, n = 83 Vim Low, n = 51
Vim Low, n = 32
Vim High, n = 59
Vim Low, n = 83
Vim High, n = 59
Vim Low, n = 51
Vim High, n = 28 Vim Low, n = 32
Vim High, n = 31
Vim High, n = 28
Vim High, n = 31
P = 0.002
P = 0.001 P = 0.029 P = 0.024
P = 0.031 P = 0.054
0 2 4 6 8 10 (years) 0 2 4 6 8 10 (years)
0 2 4 6 8 10 (years) 0 2 4 6 8 10 (years) 0 2 4 6 8 10 (years)
Disease-free survival
Overall survival
B
A
Figure 2 Survival curves were plotted using the Kaplan–Meier method for high vimentin (Vim High) expression and low (Vim Low) expression groups.
(A) Overall survival. (B) Disease-free survival. Both end points were further analysed according to tumour staging (stages II and III).
Table 2 Univariate survival analysis (disease-free survival)
Characteristics Category n 5-year survival P-value
Vimentin o8.8% 83 86.7 0.001
X8.8% 59 62.7
Age (years) o62 64 76.7 0.986
X62 78 76.9
Tumour size (cm) X5.1 71 76.1 0.881
o5.1 71 77.5
Gender Male 80 78.8 0.631
Female 62 74.2
Tumour site Colon 80 73.8 0.420
Rectum 62 80.7
Degree of differentiation Well 72 80.6 0.292
Mod./poor 70 72.9
Depth of invasion mp 13 69.2 0.376
ss 129 77.5
Lymph node metastasis Absent 79 86.1 0.004
Present 63 65.1
Lymphovascular invasion
a Absent 56 80.4 0.291
Present 86 74.4
Diffuse infiltration Absent 67 83.6 0.051
Present 79 70.7
Tumour budding Low grade (o10) 120 75.0 0.238
High grade (X10) 22 86.4
Stromal reaction Extensive 24 75.0 0.884
Moderate/slight 118 77.1
mp¼muscularis propria; ss¼subserosa.
aLymphatic invasion was determined by the
presence of tumour cells in lymphatic ducts. Bold values are statistically significant
(Po0.05).
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sVimentin is ubiquitously expressed by cells of mesenchymal
origin including fibroblasts, endothelial cells, smooth muscle cells,
leucocytes, and some other cells (Dulbecco et al,1 9 8 3 ;M o r - V a k n i n
et al, 2003). In certain carcinomas such as breast cancer or
melanoma, vimentin was upregulated in aggressive phenotypes in a
phenomenon known as epithelial–mesenchymal transition (Brabletz
et al, 2005). However, this phenomenon was not observed in CRC.
In fact, in CRC, vimentin was specifically expressed in the stroma,
but not in the tumour cells (Altmannsberger et al, 1982; von
Bassewitz et al, 1982; Sordat et al, 2000). Thus, in this study we
attempted to quantitate the expression of vimentin to verify the
clinical value of the stromal response in CRC.
We found that vimentin expression in the tumour stroma was
useful in identifying CRC patients with a poor prognosis. Increased
stromal vimentin expression indicated a dynamic change in the
tumour stroma during tumour progression. Previous attempts to
evaluate the stromal response were based mostly on histological
changes of the fibrous tissue in the stroma, including an evaluation
of the relative amount of fibrous tissue or the pattern of stroma
(Jass et al, 1986; Ueno et al, 2004). Results have been controversial
with regard to prognosis. Some suggested a positive correlation,
but others have suggested otherwise (Jass et al, 1986; Halvorsen
and Seim, 1989; Harrison et al, 1994; Ueno et al, 2004).
Nevertheless, these studies indicated that significant histological
changes could be observed in the tumour stroma.
A significant part of the change could be attributed to
fibroblastic changes, as suggested by other studies, as fibroblasts
are the main cell population in tissue stroma. Our data suggest the
possibility that stromal fibroblasts may indeed facilitate tumour
progression, possibly invasion, and metastasis, leading to a higher
rate of disease recurrence. Fibroblasts, being both activated by
cytokines and at the same time producing cytokines or other
soluble factors, were reported to modulate various aspects of
tumour progression including proliferation or invasion (Vogetseder
et al, 1989; Nakamura et al, 1997), angiogenesis (Orimo et al,
2001), or inhibition of cell death (Olumi et al, 1998). Vimentin
expression is reportedly universally found in all types of
fibroblasts (Skalli et al, 1989; Sappino et al, 1990). In comparing
the extent of stromal reaction and vimentin expression in this
study, however, our data suggest that fibrous tissue itself may not
be sufficient to promote tumour progression. Collaboration with
other factors in the stroma, including the cellular compartment
consisting of lymphocytes and endothelial cells may be necessary
to create a microenvironment favourable for tumour progression.
Other histological changes often observed in the tumour stroma
are the appearance of lymphocytes. These infiltrating lymphocytes
are known as tumour-infiltrating lymphocytes (TIL). Vimentin
expression is also found in this group of cells. Thus, increased
vimentin expression could also indicate increased numbers of TIL.
Whether this group of cells protects the host against the tumour
cells, or prevents a tumour-specific immune response, remains a
controversial topic. A gradual increase in TIL was observed during
melanoma tumorigenesis (Hussein et al, 2006). However, increased
immune cells in CRC are reportedly associated with better survival
(Pages et al, 2005). If indeed the increased vimentin is caused by
this group of cells, our results would advocate that TIL suppress
the immune response against the tumour. However, we note that
recent studies have indicated that different subsets of TIL might
have distinct roles in the tumour microenvironment (Yu and Fu,
2006).
As vimentin also stains endothelial cells, increased microvessels
in these regions also caused an increase in overall vimentin
expression in the stroma. As tumours grow, development of blood
vessels becomes necessary to provide needed oxygen and
nutrients. In CRC, the correlation between microvessel density
and prognosis has been variable, with studies indicating both
positive and negative correlations (Neal et al, 2006). In this series,
we showed that although the single factor change of microvessel
density did not provide any prognostic significance, the overall
evaluation with vimentin had useful prognostic value to differ-
entiate between high-risk and low-risk groups.
Furthermore, we found that the prognostic power of vimentin
expression was better than that of lymph node metastasis. These
data support the notion of vimentin as a novel tumour stromal
prognostic marker in CRC. We also found that the prognostic
power of vimentin was independent of lymph node status, as well
as the stage of histological differentiation. These results support
the proposal that stromal therapy may be a viable approach to
CRC. Stromal therapy was proposed to be more flexible and
applicable to a wider range of disease stages, as its target is
dynamic (Liotta and Kohn, 2001). In hepatocarcinoma, chemo-
therapy was demonstrated to be more effective, if therapies against
the underlying fibrosis were also employed (Friedman et al, 2000;
Bilimora et al, 2001). It is also of interest that stromal markers,
such as vimentin in this study, may be useful in monitoring
stromal therapies. Targeting the tumour as an organ would be
more effective than targeting the tumour alone.
Here, we provide clinical evidence of stromal response, as
evaluated by vimentin expression, as a prognostic indicator for
poor prognosis in CRC patients irrespective of lymph node status.
Vimentin staining allows an evaluation of overall stromal changes
that include fibroblastic changes, microvessel density, infiltrating
lymphocytes, and possibly other stromal changes yet to be
identified. We note, however, that although the results presented
here may be useful as a biological marker, they might not
specifically reflect the biological nature of cancer (Nishio et al,
2001). Further assessment of other stromal reaction markers
should allow a better understanding of more specific interactions
between tumour cells and the microenvironment. A larger scale
prospective study will be necessary to verify the prognostic
significance of this stromal marker.
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Table 3 Multivariate analysis (disease-free survival)
P-value Risk ratio Confidence interval
Vimentin (high: low) 0.001 3.45 1.65–7.22
Lymphovascular invasion (present: absent) 0.567 1.24 0.59–2.62
Diffuse infiltration (present: absent) 0.047 2.29 1.01–5.18
Tumour budding (high grade: low grade) 0.340 0.62 0.24–1.65
Lymph node metastasis (present: absent) 0.043 2.20 1.02–4.72
Depth of invasion (ss: mp) 0.445 0.64 0.20–2.02
Stromal reaction (extensive: moderate/slight) 0.875 1.08 0.42–2.78
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